Synthetic glycopeptide vaccines combining β-mannan and peptide epitopes induce protection against candidiasis
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
The first fully synthetic glycopeptide vaccines against a fungal disease have been used to combat disseminated candidiasis in mice. Six T cell peptides found in Candida albicans cell wall proteins were selected by algorithm peptide epitope searches; each was synthesized and conjugated to the fungal cell wall β-mannan trisaccharide [β-(Man) 3 ] by novel saccharide-peptide linker chemistry to create glycopeptide conjugates. The six proteins were selected because of expression during human candidiasis and cell wall association and included: fructose-bisphosphate aldolase (Fba); methyltetrahydropteroyltriglutamate (Met6); hyphal wall protein-1 (Hwp1); enolase (Enol); glyceraldehyde-3-phosphate dehydrogenase (Gap1); and phospho g lycerate kinase (Pgk1). By immunization protocols favoring production of protective antibody, the β-(Man) 3 -Fba, β-(Man) 3 -Met6 and β-(Man) 3 -Hwp1 induced protection evidenced by survival and reduced kidney fungal burden, the β-(Man) 3 -Eno1 and β-(Man) 3 -Gap1 gave moderate protection, and the β-(Man) 3 -Pgk1 slightly enhanced disease. For the β-(Man) 3 -Fba conjugate, protection was uniquely acquired through immunity against the carbohydrate and the Fba peptide. This approach based on fully synthetic chemically defined immunogens should be generally useful in vaccine development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A novel glyco-conjugate vaccine against fungal pathogens
Torosantucci, A., Bromuro, C., Chiani, P., De Bernardis, F., Berti, F., Galli, C., Norelli, F., Bellucci, C., Polonelli, L., Costantino, P., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050749 · Cited by 442
Robust immune responses elicited by a fully synthetic three-component vaccine
Ingale, S., Wolfert, M. A., Gaekwad, J., Buskas, T., & Boons, G.-J. (2007) · Nature Chemical Biology · doi:10.1038/nchembio.2007.25 · Cited by 337 · cited 1×
“Finally, while synthetic glycopeptide vaccines reported by others induce potentially protective antibody responses against only the carbohydrate epitope of the vaccine conjugate (34, 35), at least one conjugate reported here uniquely induces protective responses against both the carbohydrate and peptide carrier compon…”
Background
Cited by
The Fungal Cell Wall: Structure, Biosynthesis, and Function
Gow, N. A. R., Latge, J.-P., & Munro, C. A. (2017) · Microbiology Spectrum · doi:10.1128/microbiolspec.funk-0035-2016 · Cited by 1,423
“…ef fi cacious in mouse models of systemic mycoses include C. albicans vaccines based on the N-terminal regions of Als1 (193) and Als3 (194), synthetic glycopeptides that are based on epitopes of cell wall-associated proteins conjugated to mannose trisaccharides (195), and anti-Mp65 antibodies (196).”
BackgroundCarbohydrate vaccines: developing sweet solutions to sticky situations?
Astronomo, R. D., & Burton, D. R. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3012 · Cited by 629
Covalently linked cell wall proteins of Candida albicans and their role in fitness and virulence
Klis, F. M., Sosinska, G. J., de Groot, P. W. J., & Brul, S. (2009) · FEMS Yeast Research · doi:10.1111/j.1567-1364.2009.00541.x · Cited by 165
Vaccines for human fungal diseases: close but still a long way to go
Oliveira, L. V. N., Wang, R., Specht, C. A., & Levitz, S. M. (2021) · npj Vaccines · doi:10.1038/s41541-021-00294-8 · Cited by 135
Luo, G., Ibrahim, A. S., French, S. W., Edwards, J. E., & Fu, Y. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025909 · Cited by 62
“albicans vaccine development has focused on using cell surface components [18,19], peptides derived from cell wall proteins as immunogens [20], or on antibodies targeting cell surface components [21,22].”
Background
Metadata
- Authors
- Xin, H., Dziadek, S., Bundle, D. R., & Cutler, J. E.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2008-09-09
- Volume
- 105
- Issue
- 36
- Pages
- 13526-13531
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2156792116
- Cited by
- 224
- References
- 2
- FWCI
- 7.82
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.